group reported that recombinant human endostatin radiosensitized xenograthed human nasopharyngeal carcinoma in mice. But, these inhibitors have not yet been clinically used in combination with radiation therapy. VEGF is among the promising targets for anti-cancer treatment. Neutralization of VEGF inhibited the development of (-)-MK 801 primary tumors and metastases. Stopping VEGF with a neutralizing antibody enhanced the antitumor effects of light in pre-clinical studies. Yet another group reported that an anti VEGF monoclonal antibody in conjunction with radiation generated tumefaction growth delay in mouse xenograth designs. Bevacizumab is really a humanized monoclonal antibody which neutralizes the VEGF ligand. Bevacizumab in combination with cytotoxic chemotherapy showed a significant improvement in survival in patients with higher level colorectal or lung cancer. Currently bevacizumab is approved for use in combination with cytotoxic chemotherapy in those diseases. the combination therapy of bevacizumab with radiation can be a promising strategy to increase the antitumor effects. A clinical trial with a combination of radiation treatment plus 5 FU with bevacizumab followed by surgery was done and led to encouraging results in patients with locally Organism advanced rectal cancer. the mixture of radiation therapy with bevacizumab resulted in answers in locally high level inoperable colorectal cancer. the addition of bevacizumab to neoadjuvant chemoradiotherapy using capecitabine led to encouraging pathologic complete reaction with tolerable toxicity for locally advanced level rectal cancer. Further clinical studies are required to gauge the function of combination therapy of bevacizumab with radiation or chemoradiation in patients with rectal cancers. A phase II study was conducted to evaluate using bevacizumab in combination with radiation therapy and concurrent Dasatinib clinical trial capecitabine followed by maintenance gemcitabine and bevacizumab for patients with locally higher level pancreatic cancer. the median overall survival and the median progression free survival time were similar to the results obtained in preceding RTOG tests with main-stream chemoradiotherapy. this result implies that the addition of bevacizumab doesn’t enhance the efficiency of conventional chemoradiotherapy in patients with locally advanced pancreatic cancer. Currently, many clinical studies using combination treatment of bevacizumab with radiation or chemoradiation are ongoing in patients with other malignant tumors such as glioblastoma or head and neck cancers. DC101 is just a VEGFR2 antibody, and it had been reported to decrease the radiation dose necessary to control tumor models. DC101 in conjunction with radiation showed a synergistic effect when irradiation was done several days ather the administration of DC101.